Iranian Journal of Psychiatry and Behavioral Sciences

Published by: Kowsar
Crossmark

Open Trial of the Addition of Divalproex Sodium for Improving the Symptoms of Batak and Non-Batak Males with Schizophrenia in North Sumatra, Indonesia

Novi Prasanty 1 , 2 , * , Elmeida Effendy 2 , Mustafa Mahmud Amin 2 , Muhammad Joesoef Simbolon 1 , 2 , Vita Camellia 1 and Muhammad Surya Husada 1
Authors Information
1 Department of Psychiatry, Faculty of Medicine, University of Sumatera Utara, Medan, Indonesia
2 Department of Psychiatry, Faculty of Medicine, Islamic University of Sumatera Utara, Medan, Indonesia
Article information
  • Iranian Journal of Psychiatry and Behavioral Sciences: 13 (2); e68981
  • Published Online: June 15, 2019
  • Article Type: Original Article
  • Received: March 29, 2018
  • Revised: March 9, 2019
  • Accepted: May 10, 2019
  • DOI: 10.5812/ijpbs.68981

To Cite: Prasanty N, Effendy E, Amin M M, Simbolon M J, Camellia V , et al. Open Trial of the Addition of Divalproex Sodium for Improving the Symptoms of Batak and Non-Batak Males with Schizophrenia in North Sumatra, Indonesia, Iran J Psychiatry Behav Sci. Online ahead of Print ; 13(2):e68981. doi: 10.5812/ijpbs.68981.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Prasanty N, Amin MM, Effendy E, Simbolon J. Low vitamin D serum level increases severity symptoms in schizophrenic patients measured by positive and negative symptoms scale (PANSS) in batak tribe sumatera utara, Medan-Indonesia. Bali Medical Journal. 2018;7(1):249. doi: 10.15562/bmj.v7i1.921.
  • 2. Diaz-Caneja CM, Pina-Camacho L, Rodriguez-Quiroga A, Fraguas D, Parellada M, Arango C. Predictors of outcome in early-onset psychosis: A systematic review. NPJ Schizophr. 2015;1:14005. doi: 10.1038/npjschz.2014.5. [PubMed: 27336027]. [PubMed Central: PMC4849440].
  • 3. Sadock BJ, Sadock VA, Ruiz P. Schizophrenia. Kaplan and Sadock's Synopsis of psychiatry behavioral sciences/clinical psychiatry. 11th ed. Philadelphia: Lippincott Williams & Wilkins; 2015. p. 649-701.
  • 4. Tseng PT, Chen YW, Chung W, Tu KY, Wang HY, Wu CK, et al. Significant effect of valproate augmentation therapy in patients with schizophrenia: A meta-analysis study. Medicine (Baltimore). 2016;95(4). e2475. doi: 10.1097/MD.0000000000002475. [PubMed: 26825886]. [PubMed Central: PMC5291556].
  • 5. Casey DE, Daniel DG, Tamminga C, Kane JM, Tran-Johnson T, Wozniak P, et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology. 2009;34(5):1330-8. doi: 10.1038/npp.2008.209. [PubMed: 19052541].
  • 6. Horowitz E, Bergman LC, Ashkenazy C, Moscona-Hurvitz I, Grinvald-Fogel H, Magnezi R. Off-label use of sodium valproate for schizophrenia. PLoS One. 2014;9(3). e92573. doi: 10.1371/journal.pone.0092573. [PubMed: 24664210]. [PubMed Central: PMC3963914].
  • 7. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: Towards individualized pharmaceutical treatment. J Natl Med Assoc. 2002;94(10 Suppl):1-26. [PubMed: 12401060]. [PubMed Central: PMC2594139].
  • 8. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: Focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008;84(3):417-23. doi: 10.1038/clpt.2008.141. [PubMed: 18615002].
  • 9. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103-41. doi: 10.1016/j.pharmthera.2012.12.007. [PubMed: 23333322].
  • 10. Heriawan R. Kewarganegaraan, suku bangsa , agama, dan bahasa sehari-hari penduduk Indonesia. Jakarta: Badan Pusat Statistik; 2011. p. 1-13.
  • 11. Sastroasmoro S, Ismail S. Dasar-dasar metodologi penelitian klinis. Third ed. Jakarta: Sagung Seto; 2008.
  • 12. Dahlan MS. Besar Sampel dalam penelitian kedokteran dan kesehatan. Third ed. Jakarta: Salemba Medika; 2013.
  • 13. Opler LA, Opler MG, Malaspina D. Reducing guess work in schizophrenia treatment, panss can target gauge therapy predict outcomes. Curr Psychiatr. 2006;5(9):76-84.
  • 14. Stahl SM. Essential psychopharmacology prescriber's guide. New York: Cambridge University Press; 2015. p. 711-7.
  • 15. Dahlan MS. Statistik untuk kedokteran dan Kesehatan: Deskriptif, bivariat dan multivariat, dilengkapi dengan menggunakan SPSS. Third ed. Jakarta: Sagung Seto; 2015.
  • 16. Rajamarpondang GD. Dahlihan na tolu dan prinsip dasar nilai budaya batak. 1 ed. Medan: Deposit daerah Sumatera Utara; 2010.
  • 17. Glick ID, Bosch J, Casey DE. A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive. J Clin Psychopharmacol. 2009;29(3):267-71. doi: 10.1097/JCP.0b013e3181a443d0. [PubMed: 19440081].
  • 18. Ayano G. Bipolar disorders and valproate: Pharmacokinetics,pharmacodynamics, therapeutic effects and indications of valproate: Review of articles. Bipolar Disord. 2016;2(2):1-5. doi: 10.4172/2472-1077.1000109.
  • 19. Suzuki T, Uchida H, Takeuchi H, Nakajima S, Nomura K, Tanabe A, et al. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Hum Psychopharmacol. 2009;24(8):628-38. doi: 10.1002/hup.1073. [PubMed: 19946935].
  • 20. Guidotti A, Dong E, Kundakovic M, Satta R, Grayson DR, Costa E. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol Sci. 2009;30(2):55-60. doi: 10.1016/j.tips.2008.10.010. [PubMed: 19110320].
  • 21. Dong E, Chen Y, Gavin DP, Grayson DR, Guidotti A. Valproate induces DNA demethylation in nuclear extracts from adult mouse brain. Epigenetics. 2010;5(8):730-5. doi: 10.4161/epi.5.8.13053. [PubMed: 20716949].
  • 22. Christian Machado Ximenes J, Crisóstomo Lima Verde E, da Graça Naffah-Mazzacoratti M, Socorro de Barros Viana G. Valproic acid, a drug with multiple molecular targets related to its potential neuroprotective action. Neurosci Med. 2012;3(1):107-23. doi: 10.4236/nm.2012.31016.
  • 23. Abad N MH, Ghaffarian Shirazi HR, Mohammadi A, Kashkouli Behroozi M, Hosseini Mehrian Z; N. Sodium valproate as an adjunctive to trifluoperazine in the treatment of schizophrenia. J Am Sci. 2013;9(10s):60-2.
  • 24. Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatr Serv. 2004;55(3):290-4. doi: 10.1176/appi.ps.55.3.290. [PubMed: 15001730].
  • 25. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology. 2003;28(1):182-92. doi: 10.1038/sj.npp.1300023. [PubMed: 12496955].
  • 26. Sim K, Yong KH, Chan YH, Tor PC, Xiang YT, Wang CY, et al. Adjunctive mood stabilizer treatment for hospitalized schizophrenia patients: Asia psychotropic prescription study (2001-2008). Int J Neuropsychopharmacol. 2011;14(9):1157-64. doi: 10.1017/S1461145711000563. [PubMed: 21557883].
  • 27. Sajatovic M, Coconcea N, Ignacio RV, Blow FC, Hays RW, Cassidy KA, et al. Adjunct extended-release valproate semisodium in late life schizophrenia. Int J Geriatr Psychiatry. 2008;23(2):142-7. doi: 10.1002/gps.1854. [PubMed: 17582828].
  • 28. Omranifard V, Amel AK, Amanat S. Sodium valproate as adjunctive drug in treatment of schizophrenia. Iran J Psychiatry Behav Sci. 2007;1(1):12-5.
  • 29. Basan A, Kissling W, Leucht S. Valproate as an adjunct to antipsychotics for schizophrenia: A systematic review of randomized trials. Schizophr Res. 2004;70(1):33-7. doi: 10.1016/j.schres.2004.01.016. [PubMed: 15246461].
  • 30. Kelly DL, Conley RR, Feldman S, Yu Y, McMahon RP, Richardson CM. Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatr Q. 2006;77(1):81-95. doi: 10.1007/s11126-006-7963-9. [PubMed: 16397757].
  • 31. Gobbi G, Gaudreau PO, Leblanc N. Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. J Clin Psychopharmacol. 2006;26(5):467-73. doi: 10.1097/01.jcp.0000237945.35022.45. [PubMed: 16974186].
  • 32. Tarigan RW, Syamsir BS. Perbedaan efektifitas haloperidol tunggal dan haloperidol dengan sodium divalproex terhadap keparahan pasien skizofrenia paranoid. Program magister kedokteran klinik ppds-i ilmu kedokteran jiwa. University Sumatera Utara; 2009.
  • 33. Suciati R, Agung IM. Perbedaan ekspresi emosi pada orang Batak, Jawa, Melayu dan Minangkabau. J Psikologi. 2017;12(2):99-108. doi: 10.24014/jp.v12i2.3236.
  • 34. Yolanda WG, Wismanto YB. Perbedaan regulasi emosi dan jenis kelamin pada Mahasiswa yang bersuku Batak dan Jawa. Psikodimensia. 2017;16(1):72-80. doi: 10.24167/psiko.v16i1.948.
  • 35. Kurniawan AP, Hasanat NU. Perbedaan ekspresi emosi pada beberapa tingkat generasi suku jawa di yogyakarta. Psychol J Fac Psychol Gadjah Mada Univ. 2004;34(1):1-17. doi: 10.22146/jpsi.7086.
  • 36. Citrome L, Shope CB, Nolan KA, Czobor P, Volavka J. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Int Clin Psychopharmacol. 2007;22(6):356-62. doi: 10.1097/YIC.0b013e3281c61baf. [PubMed: 17917554].
  • 37. Vincenzi B, Greene CM, Ulloa M, Parnarouskis L, Jackson JW, Henderson DC. Lithium or valproate adjunctive therapy to second-generation antipsychotics and metabolic variables in patients with schizophrenia or schizoaffective disorder. J Psychiatr Pract. 2016;22(3):175-82. doi: 10.1097/PRA.0000000000000149. [PubMed: 27123797]. [PubMed Central: PMC5331927].
  • 38. Winter HR, DeVane CL, Figueroa C, Ennis DJ, Hamer-Maansson JE, Davis PC, et al. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Hum Psychopharmacol. 2007;22(7):469-76. doi: 10.1002/hup.869. [PubMed: 17729385].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments